Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
A class of drug called monoamine oxidase inhibitors is commonly prescribed to treat depression; the medications work by boosting levels of serotonin, the brain's "happiness hormone."
A new study published today in Cancer Discovery, a journal of the American Association for Cancer Research, reports findings that may change the understanding of how synovial sarcoma develops and spreads.
Patients with high-risk melanoma who had a course of pembrolizumab after their surgery had a longer time before their disease recurred than patients who got either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, will be presented at the ASCO annual meeting June 6, 2021.
Melanoma accounts for only about 1% of skin cancers but leads to most of the skin cancer-related deaths.
Many patients with cancer receive immune checkpoint inhibitors that strengthen their immune response against tumor cells. While the medications can be life-saving, they can also cause potentially life-threatening side effects in internal organs.
Parkinson’s disease is a neurodegenerative disorder and melanoma is a type of skin cancer but on the surface, these disorders do not seem to have much in common.
A pre-clinical study for melanoma and neuroblastoma shows that a customized tumor cell vaccine technique that targets Myc oncogenes coupled with checkpoint therapy produces an active immune response that bypasses antigen selection and immune privilege.
A team of researchers has studied the molecular profile of small “messenger” vesicles called exosomes, produced by cancer stem cells (CSCs), which play a key role in the process of carcinogenesis and metastasis in the blood of patients with malignant melanoma.
A few patients suffering from melanoma are known to respond quite well to immunotherapy and experience significant and long-lasting tumor regression.
Immunotherapy, which recruits the body's own immune system to attack cancer, has given many cancer patients a new avenue to treat the disease.
Cancer immunotherapy may get a boost from an unexpected direction: bacteria residing within tumor cells. In a new study published in Nature, researchers at the Weizmann Institute of Science and their collaborators have discovered that the immune system "sees" these bacteria and shown they can be harnessed to provoke an immune reaction against the tumor.
Low representation of minority groups in public genomic databases may affect therapy selection for Black patients with cancer, according to new Mayo Clinic research published in npj Precision Oncology.
Results from a study led by Joan Seoane, Director of Preclinical and Translational Research co-program at VHIO and ICREA Professor, show that immune cells accessing cerebrospinal fluid faithfully recapitulate the characteristics of cells identified in brain metastasis, and could therefore constitute novel biomarkers of response to immune-based therapies.
WEHI researchers have uncovered a process cells use to fight off infection and cancer that could pave the way for precision cancer immunotherapy treatment.
By harnessing the immune system against cancer, immunotherapies have revolutionized the way some types of cancer are treated. But most patients--across cancer types--do not respond, and in most cases, scientists are at a loss as to why.
Developing “super soldiers” of particular white blood cells to promote an anti-tumor reaction has been demonstrated in a series of well-designed experiments.
Recently, messenger RNA, also called mRNA, vaccines, to combat the COVID-19 infection have made headlines worldwide, but researchers have already been experimenting with mRNA vaccines to prevent or cure other illnesses, including certain types of cancer.
Statistical modeling developed by Oregon State University researchers has confirmed that changes to melanoma patients' gut microbiome led them to respond to a type of treatment capable of providing long-term benefit.
A study has revealed how chemicals surrounding tumors, the tumor microenvironment, undermine the immune system and allow cancer to resist attack.
A paper published today in Nature shows how chemicals in the areas surrounding tumors--known as the tumor microenvironment--subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.